COVISHIELD phase 2, 3 trials get DCGI nod

sfg-2026
ForumIAS LATEST
      1. SFG 2027 Level-1 starts 21 Dec. 2026 at 7 AM | Entrance Test on 22 Nov. at 9:30 AM Click Here to know more →
      2. Interview Guidance initiative by ForumIAS – UPSC CSE 2026 Click Here to know more →
      3. FRC 2027: SFG Residential program | accepting application for Tranche-2 Click Here to know more →

News: Drugs Controller General of India(DCGI) has given approval to Serum Institute of India(SII) to conduct Phase II+III clinical trials of Oxford University AstraZeneca COVID-19 vaccine(COVISHIELD).

Facts:

  • COVISHIELD: The Oxford vaccine “AZD1222” is being called Covishield in India.
  • The Serum Institute of India(SII) has entered into a manufacturing partnership with biopharma major AstraZeneca to produce this Oxford vaccine.

Additional Facts:

  • DCGI: It is a department of the Central Drugs Standard Control Organization(CDSCO) responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids and vaccines in India.It comes under the Ministry of Health & Family Welfare.
  • Case Fatality Rate(CFR): It is the proportion of deaths from a certain disease compared to the total number of people diagnosed with the disease for a particular period.
Print Friendly and PDF
Blog
Academy
Community